
NeuroSync is a digital health company providing AI-powered, customizable brain health and performance assessment solutions using a wireless Virtual Reality platform. Their flagship product, EYE-SYNC, is FDA-cleared and offers fast, accurate, and reliable diagnostics for neuro health conditions, supporting clinical care, research, and high-performance optimization in healthcare, biopharma, sports, and military sectors. The company leverages proprietary algorithms and objective eye-tracking metrics validated by independent research, enabling clinicians and researchers to identify deficits, monitor drug responses, and plan training. NeuroSync's technology addresses a significant market need for validated neuro diagnostics, with a scalable platform used by top healthcare and sports organizations.

NeuroSync is a digital health company providing AI-powered, customizable brain health and performance assessment solutions using a wireless Virtual Reality platform. Their flagship product, EYE-SYNC, is FDA-cleared and offers fast, accurate, and reliable diagnostics for neuro health conditions, supporting clinical care, research, and high-performance optimization in healthcare, biopharma, sports, and military sectors. The company leverages proprietary algorithms and objective eye-tracking metrics validated by independent research, enabling clinicians and researchers to identify deficits, monitor drug responses, and plan training. NeuroSync's technology addresses a significant market need for validated neuro diagnostics, with a scalable platform used by top healthcare and sports organizations.
Founded: 2009
Headquarters: Palo Alto, California
Core product: EYE-SYNC head-mounted eye-tracking/VR system
Total disclosed funding: USD 3,600,000
Employee count (reported): 43
Objective, rapid assessment and monitoring of brain function (concussion, attention, neuro health) using eye-tracking and VR.
2009
Neuro-technology / Digital health
Most recent disclosed round listed on March 11, 2019
“Company reported to have multiple investors (reported as six), including StartUp Health and Raul Fernandez”